Novel three-antigen HSV-2 subunit vaccine as well as preparation method and application thereof

By preparing a triantigen HSV-2 subunit vaccine containing HSV-2 gB2, gC2, gD2 envelope glycoproteins, CpG oligonucleotides, and aluminum adjuvant, the problem of existing HSV-2 vaccines being unable to effectively prevent HSV-2 has been solved, achieving highly efficient immune protection against HSV-1 and HSV-2.

CN121754656APending Publication Date: 2026-03-31INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
3 Cites 1 Cited by

Patent Information

Application Number
CN202610251642.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-03
Publication Date
2026-03-31

AI Technical Summary

Technical Problem

Existing HSV-2 vaccines are ineffective in preventing and treating herpes simplex virus infection, and existing drugs can only inhibit viral replication but cannot eradicate the virus or prevent frequent reactivation. There is an urgent need to develop safe and effective vaccines and treatments.

Method used

A novel triantigen HSV-2 subunit vaccine, comprising a combination of HSV-2 gB2, gC2, and gD2 envelope glycoproteins with CpG oligonucleotides and aluminum adjuvant, was prepared using a baculovirus-insect cell expression system and validated in mice, inducing high-titer specific IgG antibodies and cellular immune responses.

Benefits of technology

High-titer specific IgG antibodies were induced in mice, which could effectively neutralize HSV-1 and HSV-2, showing good immunogenicity and cross-protection, and providing a new HSV-2 vaccine development strategy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.
Need to check novelty before this filing date? Find Prior Art